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PreviewsThese two ground-breaking reports
provide exciting clues regarding the
transcriptional circuitry that controls the
terminal maturation of CD8aa+ IELs, and
uncover a role of T-bet in this process.
Together, their findings raise some ques-
tions about the relationships between
natural, induced, and developmentally
diverted CD8aa+ IELs. For example,
Reis et al. demonstrated that the differen-
tiation of induced CD8aa+ IELs revolves
around T-bet-mediated upregulation of
Runx3, whereas Klose et al. reported
that IL-15 can induce Runx3 expression
in thymic IEL precursors independently
of T-bet. It is possible that these con-
trasting observations on the regulation
of Runx3 expression reflect epigenetic
differences that have yet to be eluci-
dated, between thymic IELPs and mature
conventional TCRab+ T cells in the pe-
riphery prior to initiation of CD8aa+ IEL
differentiation. Nevertheless, the fact
that normal levels of Runx3 expression
in Tbx21–/– thymic IELPs were not suffi-
cient for the development of natural
Tbx21–/– CD8aa+ IELs in the gut indicates
that natural CD8aa+ IELs, similar to
induced CD8aa+ IELs, depend on theconcerted expression and cooperative
action of T-bet and Runx3 for their
development. Furthermore, while IL-15
signaling mediates the survival of
CD8aa+ IELs by inducing expression of
the antiapoptotic protein Bcl2, overex-
pression of Bcl2 in Tbx21–/– mice did
not restore the CD8aa+ IEL compart-
ment, suggesting that the requirement
for T-bet in CD8aa+ IELs is not solely
limited to the regulation of CD122 (Klose
et al., 2014b). It remains to be seen
whether additional target genes, directly
or indirectly downstream of T-bet, play
a similarly critical role in the differen-
tiation, maintenance, or function of either
natural or induced CD8aa+ IELs. With
that in mind, Klose et al. and Reis et al.
have provided an intriguing framework
from which future studies can be devel-
oped in order to unravel the complexities
of these (and other) intestinal lymphocyte
populations that are so critical to healthy
gut homeostasis.REFERENCES
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In this issue of Immunity, Wu et al. (2014) report that galectin-9 is required for the formation and stability of
iTreg cells. Galectin-9 interacts with CD44 in association with TGF-b receptors to drive both Foxp3 and
galectin-9 expression in a positive-feedforward loop involving Smad3 activation.T cells are super cells that can do almost
anything. They differentiate to fit their su-
per tasks in the right environment and
with the proper instruction. Being super,
they also command order by dominant-
negative regulation of other cells. Regu-
latory T cells (Tregs) take the lead in
regulating immune homeostasis, auto-
immunity, and responses to infection,
cancer, and inflammation (Curotto de La-
faille and Lafaille, 2009). But even supercells have their masters, and one of these
is Foxp3 (Forkhead box P3), an X-linked
transcription factor that defines the
functions of thymus-derived natural Treg
(nTreg) cells versus adaptive or induced
Treg (iTreg) cells. The differentiation of
peripheral naive T cells into Foxp3+ iTreg
cells is mainly driven by both cytokines
transforming growth factor b (TGF-b),
which drives Foxp3 expression, and inter-
leukin-2 (IL-2), which drives cell growth(Ouyang et al., 2010). But optimal expres-
sion of Foxp3 is further dependent on
Smad3, a transcriptional modulator that
is induced by Foxp3 itself, which further
enhances Foxp3 expression (Derynck
and Zhang, 2003). But many other factors
yet to be defined also contribute to stable
iTreg formation.
Wu et al. have now provided unique in-
sights into one key factor that contributes
to stable formation of iTreg cells via, August 21, 2014 ª2014 Elsevier Inc. 171
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2014). The factor required for iTreg cell
function is galectin-9, a soluble tandem-
repeat member of the galectin family
found both in the cytoplasm and outside
cells. Galectin-9 might have a unique
binding specificity for glycans among
other types of carbohydrate-binding pro-
teins, because it prefers long chains of
nonsialylated poly-N-acetyllactosamine
repeats (3Galb1-4GlcNAcb1-)n (Nagae
et al., 2009). Galectin-9 is widely ex-
pressed and has been long implicated in
T cell biology. The protein is a binding
partner of the Tim-3 inhibitory receptor
and potentially involved in suppressing
T helper 1 (Th1) cells in tolerogenic
responses (Zhu et al., 2005), as well as
having Tim-3 independent functions.
A key prior insight into galectin-9 func-
tion is that mice lacking galectin-9 exhibit
decreased expression of FoxP3+ Treg
cells (Seki et al., 2008).
To explore physiological roles of
galectin-9 in Treg cell development,
Wu et al. (Wu et al., 2014) used such
galectin-9 deficient mice (Lgals9/).
While these animals have normal T cell
development in lymphoid organs, they
exhibit reduced frequency of iTreg
cells in the lamina propria of the small
bowel, but no major differences in the
frequency of nTreg cells. More impor-
tantly, the Lgals9/ T cells are defective
in Foxp3 expression. Application of ex-
ogenous recombinant galectin-9 stimu-
lated Foxp3 expression synergistically
with TGF-b. Similarly, exogenous galec-
tin-9 induced iTreg cell differentiation in
a lactose-inhibitable fashion, and this
effect is not seen for other T cell subsets.
(Lactose, although a weak inhibitor of
galectins in general, can potently inhibit
galectin binding at high millimolar con-
centrations.) The data indicates that
both in vivo and in vitro galectin-9 partic-
ipates in iTreg differentiation via binding
to glycan-dependent receptors on the
cell surface.
But questions arise in working with
galectins, because they are the only
glycan-binding proteins that are synthe-
sized in the cytoplasm on membrane-
free ribosomes, and also exit to the cell
surface and extracellular milieu, perhaps
by partnering with ligands in some unique
fashion. Thus, the question arises as to
whether galectin-9 signaling is func-
tioning intracellularly or extracellularly. If172 Immunity 41, August 21, 2014 ª2014 Elsfunctioning is extracellular, then Lgals9/
T cells might be instructed by heterolo-
gous contact with galectin-9 supplied by
other cells, whereas if it is intrinsic, then
galectin-expressing host cells would be
less effective in such heterologous
signaling. Wu et al. conducted this key
experiment by using CD45.1+ cells from
WT mice and CD45.2+ T cells in the
Lgals9/ mice. Coculture of the two
types of T cells partly corrected the
deficiency in Foxp3 expression of the
CD45.2+ Lgals9/ T cells, and transfer
of CD45.2+ Lgals9/ T cells into WT
mice elevated Treg cell numbers in
different organs to comparable numbers
to WT T cells. Thus, heterologous contact
with extracellular galectin-9 can restore
Treg cell functions. Consistent with this
possibility, that Lgals9/ mice were
impaired in their response to ovalbumin,
but the transfer of Lgals9/ OVA specific
T cells (OT-II), generated by crossing
Lgals9/ mice with Rag2/ OT-II mice,
resulted in a more normal frequency of
Foxp3+ iTreg cells in the CD45.2+ T cells
in Peyer’s patches. In regard to expres-
sion of galectin-9 in T cells, Wu et al.
found that galectin-9 expression was
higher in CD4+ T cells than other T cells
subsets, but was higher in iTreg than
nTreg cells. Moreover, expression of
galectin-9 itself was upregulated within
12 hr following activation by TGF-b.
This is where the story gets even more
interesting. Given the evidence that ex-
ogenous galectin-9 induces iTreg cell dif-
ferentiation, as does TGF-b, the authors
hypothesized that this upregulation of
galectin-9 induced by TGF-b might lead
to a positive-feedforward loop. Indeed,
the authors found that Smad3 bound to
multiple sites of the Lgals9 promoter in
iTreg cells, but not in Th0 cells; Smad3
transactivated the Lgals9 promoter with
costimulation via T cell receptor signaling;
and, as might be predicted from those
results, Smad3/ iTreg cells showed
reduced Foxp3 and galectin-9 expres-
sion. Overall, the results predict that
galectin-9 expression is required for effi-
cient iTreg cell expression and suppres-
sive activity. Evidence for this was found
in the mice, where WT iTreg cells, but
not galectin-9-deficient iTreg cells, were
able to suppress intestinal inflammation.
But in regard to galectin-9 signaling in
iTreg cells, what is the surface recep-
tor(s)? Prior studies implicate both Tim-3evier Inc.and CD44 as ligands for galectin-9, but
Wu et al. found that Tim-3 was not
expressed on iTreg cells. Thus, they
turned their focus to CD44, a hyalur-
onan-binding protein that was shown
some years ago to form a complex with
TGF-bRI (Bourguignon et al., 2002). Wu
et al. found that TGF-b caused cocluster-
ing of TGF-bRs with CD44 on WT iTreg
cells, but not on Lgals9/ iTregs, sug-
gesting that CD44 is a functional ligand
for galectin-9.
In tying together the signaling path-
ways, Wu et al. found that phosphoryla-
tion of Smad3 is defective in Lgals9/
T cells stimulated by TGF-b, and chro-
matin immunoprecipitation (ChIP) assays
showed reduced Smad3 interactions
with the CNS1 enhancer region of Foxp3
in Lgals9/ iTregs. Furthermore, an early
response of iTreg cells in the presence
of galectin-9 is accelerated histone modi-
fications. The importance of CD44 as a
galectin-9 ligand was verified by anti-
CD44 blocking antibody, which limited
the synergistic effects of galectin-9 and
TGF-b in inducing Foxp3 expression, as
was also observed in Cd44/ iTreg cells.
All of these results point to a model
shown in Figure 1 whereby CD44 on
iTregs functions via its specific glycosy-
lation as a ligand for galectin-9, which
amplifies TGF-b signaling via TGF-bRI to
further activate Foxp3 expression and
subsequent Smad phosphorylation, along
with enhanced galectin-9 expression.
Prior studies also find that CD44 ligation
can deliver costimulatory responses to
Treg cells via activation of the T cell
receptor (Bollyky et al., 2009). Thus,
galectin-9 has a key regulatory role in
T cell functionality, when one combines
the current results showing that galectin-
9 promotes the differentiation of Foxp3+
iTreg cells with other studies indicating
that galectin-9 can induce T cell exhaus-
tion of previously differentiated effector
T cells through its Tim3-dependent action
(Zhu et al., 2005). Stable expression of
Foxp3 in iTreg cells requires galectin-9,
thus implicating this galectin as a key
player in inflammatory responses. Galec-
tin-9 might function in a broad-based
balancing act between pro- and anti-
inflammatory responses.
The discovery here has raised many
new and exciting questions. What are the
glycans on CD44 recognized by galectin-
9? How does galectin-9 organize a
Figure 1. Galectin-9 Signals iTregs through Interactions with CD44
The cell-surface interactions involving galectin-9 binding to glycans on CD44
and potential crosslinking, in cooperation with activated TGF-bR through its
interactions with TGF-b, lead to phosphorylation and activation of Smad3.
TGF-b ligand bridges the two signaling chains of the TGF-bR. Subsequently,
the receptor-ligand complexes are recruited to CD44 on the plasma mem-
brane whereby galectin-9 engagement of CD44 leads to enhanced activation
of Smad3. Translocation of Smad3 and its association with binding partners in
the nucleus lead to transcriptional upregulation of Foxp3 and galectin-9
through promoters on Foxp3 and Lgals9 and increased production of the
proteins. A potential feedforward loop is created whereby stimulation involving
galectin-9 stabilizes expression of Foxp3 and galectin-9. Based on the results
of Wu et al.
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i.e., does galectin-9 bind
TGF-bR directly or indirectly
through organizing the pre-
sentation of CD44 in some
way? It is likely that many
other glycoproteins also bind
galectin-9, thus, how are in-
teractions among galectin-9
receptors coordinated at the
cell surface? Galectin-9 is
bivalent, so does its signaling
require crosslinking of CD44
or crosslinking it to TGF-bR?
The studies by Wu et al. sug-
gest that external sources
of galectin-9 function in
signaling. How is galectin-9
exported from cells to the
outside, and how and when
do T cells encounter galec-
tin-9? Finally, galectin-9 has
also been implicated in other
types of signaling, e.g., via
Tim-3-dependent neutrophil-
mediated killing of gram-
negative bacteria (Vega-Car-
rascal et al., 2014). Thus,
does galectin-9 have even
broader functions in this
regard along with other tan-
dem-repeat galectins thathave recently been shown to kill bacteria?
The larger picture of the study by Wu
et al. is to not only shed light on the regu-
latory functions of galectin-9 in T cell
biology, but to highlight the unique role
of glycoprotein and galectin partnering in
specific biological pathways in vivo.
Many questions have arisen about the
multiple physiological functions of galec-tins based on in vitro studies that often
provide contradictory and confusing re-
sults. The availability of defined mouse
models of galectin deficiency, as explored
here by Wu et al. with such elegance, will
provide unique and important insights into
the roles of the mysterious galectin family
in homeostasis and disease and further
our understanding of the affectionateImmunity 41, August 21relationship between these
interesting poly-N-acetyllac-
tosamine binding proteins
and T lymphocytes.REFERENCES
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